On April 13, 2021 HTL , world leader in biotechnology solutions based on hyaluronic acid (HA) and other biopolymers, and Echelon Biosciences Inc. , global supplier of biochemical reagents, tests and Services for US-based Research and Development Laboratories reported a new partnership (Press release, Echelon Biosciences, APR 13, 2021, View Source [SID1234577993]). This partnership concerns the distribution of HA and high quality glycosaminoglycans (GAGs) as well as the development of new GAGs.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This collaboration allows university research and pharmaceutical development laboratories to have access to a wide range of products based on hyaluronic acid and glycosaminoglycans (GAG), compliant with good manufacturing practices (GMP). By providing researchers with superior quality, clinical grade products at the early stages of research, the partnership aims to bridge the gap between laboratory research, development and commercialization, and accelerate innovation around the world.
"Innovation is at the heart of HTL’s DNA," said HTL CEO Yvon Bastard . "This line of development is fully in line with our mission and our vision: to provide science today with the means to develop products that will improve health in the world in the future".
"This new partnership provides scientists and researchers with key technologies to develop innovative biopolymer solutions for new medical applications in the fields of aesthetics, ophthalmology, rheumatology, tissue engineering and drug administration, "said Charles Ruban , deputy CEO of HTL. "This is the true meaning of the signature of HTL: ‘Beyond, together’. HTL’s ambition is not only to develop its leading position in the production and distribution of hyaluronic acid around the world, but also to build the solutions of tomorrow based on glycosaminoglycans ".
"With hyaluronic acid and HTL’s other GAG-based products, Echelon is giving itself the opportunity to expand its line of industry-leading HA-based extracellular kits, tests and matrices. HTL is internationally recognized for its production of premium quality biopolymers. Says Bert Israelsen , President of Echelon Biosciences . "Echelon offers its customers access to innovative tools and unparalleled technical support, thereby maximizing creativity in basic and applied research. With its fermentation and organic synthesis platforms, HTL creates functionalities and added value by developing chemically modified biopolymers, targeted for specific needs ".
"This new partnership is an important step in the deployment of HTL in the North American market and to the American medical community," said Glenn Prestwich, Ph.D. , One of the founders of Echelon and today hui expert in science and innovation at HTL. By entrusting Echelon with the distribution of its hyaluronic acid and research glycosaminoglycans products, HTL aims to increase its support and participation in biopolymer research in the United States and globally, as well as its ability to research and development.
"This new initiative is a testament to HTL’s determination to invest in healthcare innovation," said Humberto C. Antunes , HTL strategic advisor and former CEO of Galderma. He added: "In the areas of health and wellness, the biotechnology ecosystem for innovation, incubators and established and emerging companies is incredibly vibrant in the United States, Mexico and Canada. . This means enormous growth potential for HTL’s products ".